Copay Assistance: The Epipen Example

What happens when a patient uses a copay coupon?
Originally published on 06/06/2017

A real world example of Mylan's copay coupon for Epipens to demonstrate the effects of such copay assistance programs.

With the rising costs of specialty therapies, patients are increasingly turning to copay assistance programs and copay coupons offered by manufacturers to alleviate the financial toxicity associated with the costs of their drugs. Simultaneously, pharmaceutical companies are offering more and more of these coupons- a NEJM Perspective by Dafny et al. estimated that half of noninjectable, brand-name drug revenue was derived from drugs with copayment coupons in 2010, a twofold increase since 2007.

While copay coupons superficially appear to benefit patients, they actually contribute to increasing health care costs. Dafny et al.'s team concluded that between 2007 and 2010, spending on 23 drugs with coupons was $700M to $2.7B higher than if coupons had not been utilized. The harms of such programs were also detailed in the Annals of Internal Medicine, in a piece by Drs. Peter A. Ubel and Peter B. Bach:

It might seem like a reasonable deal for everyone when pharmaceutical companies fund a portion of the price of their own medications through coupons or charitable contributions. But pharmaceutical companies do not offer assistance for all filled prescriptions, only for those that patients fill before their insurance kicks in. When patients reach their out-of-pocket maximums, insurers pay all future costs. Because insurers cannot distinguish between payments from patients and copay coupons, the coupons can be used to speed patients to their out-of-pocket maximum even when they have not paid the share their insurance plan requires.

The transactions displayed in the image below (download full-size slide here) show a real-world interaction on April 29, 2017 between a patient, pharmacy, manufacturer, and insurer involving the use of a copay coupon. Mylan Pharmaceuticals offers a $300 coupon for patients to use to purchase a 2-pack of Epipens, which costs $610.48. When the patient arrived at the pharmacy to pick up the prescription, they presented the coupon and were asked to pay the remainder of the cost, $310.48. The pharmacy dispensed the drug for $310.48, but still reported to the patient's insurance plan that the customer had paid the full price of $610.48. The plan recorded this as the patient's expenditure and applied it to their deductible, even though the patient only covered half the cost. In this way, copay coupons allow patients to artificially accelerate through their out-of-pocket maximum, shifting the financial responsibility of drug costs to the insurer.


Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Copay Assistance for Expensive Drugs: A Helping Hand That Raises…
Copy assistance programs may seem to benefit public health and lower the costs of drugs, but they actually raise the costs of health care in the future.
Annals of Internal Medicine 12/20/2016
The Conflict Between QALYs and Well-Funded Patient Advocacy Groups
The goal of a QALY is to figure out how much any given drug is worth to a society so that we, as a society, have a benchmark to evaluate the price of pharmaceutical products.
Relentless Health Value 12/10/2020
Remdesivir Less Expensive for "Government Programs"? Not So Fast.
Two options are proposed if Gilead wishes to offer the discounts to the full array of government programs.
Drug Pricing Lab 07/01/2020
Blueprints for Indication-Specific Pricing
Several approaches that rewire existing reimbursement conventions as alternatives to facilitate ISP are proposed.
Drug Pricing Lab 05/19/2020
Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
Drop in Cancer Deaths Reflect Failures of Our Society. Really.
Despite declining cancer death rates, the nation still presents societal failures to improve the state of our population's health.
The Boston Globe 02/21/2020
Dissecting PhRMA's Opposition to H.R. 3 Lower Drug Costs Now…
Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.
STAT News 10/11/2019
Time to Throw in the Towel on Biosimilars
Peter Bach and Mark Trusheim of MIT Sloan School of Management underscore the drawbacks of Washington's preferred solution to introduce competition for biologics, the biosimilar model.
The Wall Street Journal 08/21/2019
Mortgaging New Treatments Kicks the Can on High Drug Prices
The launch price for one-time gene therapy Zolgensma presents various implications.
Morning Consult 07/09/2019
A $475,000 price tag for a new cancer drug: crazy…
Drug Pricing Lab op-ed in STAT News discusses indication-specific pricing of Kymriah.
STAT News 08/31/2017
US Drug Prices And R&D, Take 2: A Reply To…
To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.
Health Affairs Blog 07/27/2017
Prevalence of Off-Label Use and Spending Among Patent-Protected Chemotherapies
The prevalence of off-label anticancer drug use is not well characterized.
JCO 02/19/2013

Stay up to date on our work and news